Skip to main content
. 2013 May 10;305(1):L73–L81. doi: 10.1152/ajplung.00400.2012

Fig. 5.

Fig. 5.

ECFC-CM augments AT2 cell growth in hyperoxia. A: treatment of AT2 cells in RA with term ECFC-CMRA, preterm ECFC-CMRA, or HUVEC-CMRA for 4 days had no effect on AT2 growth. B: in hyperoxia, AT2 growth was significantly decreased. Term and preterm ECFC-CMRA, but not HUVEC-CMRA restored AT2 growth to RA levels. *P < 0.05.